Gerard Falgoust, MD
Internal Medicine · Plaquemine, LANPI 1720167869
Payments from drug & device makers
Across 169 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$614
- Teva Pharmaceuticals USA, Inc.$413
- Novo Nordisk$267
- Otsuka America Pharmaceutical, Inc.$209
- Lilly USA, LLC$161
- Lundbeck LLC$147
- plus $979 from 24 others
What the payments were for
- Food & beverage$2,67296%
- Education$1184%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $614 |
| Teva Pharmaceuticals USA, Inc. | 14 | $413 |
| Novo Nordisk | 17 | $267 |
| Otsuka America Pharmaceutical, Inc. | 13 | $209 |
| Lilly USA, LLC | 10 | $161 |
| Lundbeck LLC | 7 | $147 |
| Amarin Pharma, Inc. | 6 | $110 |
| AstraZeneca | 7 | $109 |
| Pfizer | 5 | $101 |
| Abbott | 4 | $87 |
| Phathom Pharmaceuticals, Inc. | 4 | $75 |
| Exact Sciences | 4 | $64 |
| Bayer | 3 | $53 |
| Neurocrine Biosciences, Inc. | 3 | $49 |
| Novartis | 3 | $44 |
| Sunovion Pharmaceuticals Inc. | 4 | $35 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Ardelyx, Inc. | 1 | $26 |
| Adlon Therapeutics L.p. | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Amgen | 1 | $19 |
| Smith+Nephew | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| GSK | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$2,790 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 201 | $791,894 |
| EliquisApixaban | 496 | $188,405 |
| OzempicSemaglutide | 137 | $178,028 |
| JardianceEmpagliflozin | 328 | $148,227 |
| Invega SustennaPaliperidone Palmitate | 41 | $123,557 |
| MounjaroTirzepatide | 90 | $112,199 |
| SantylCollagenase Clostridium Hist. | 36 | $82,580 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 17 | $71,651 |
| AustedoDeutetrabenazine | 24 | $64,965 |
| TrulicityDulaglutide | 39 | $51,444 |
| LinzessLinaclotide | 76 | $44,169 |
| Risperdal ConstaRisperidone Microspheres | 51 | $34,087 |
| TradjentaLinagliptin | 67 | $32,509 |
| RestasisCyclosporine | 51 | $31,930 |
| Cyclosporine | 92 | $30,812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $49 | $791,894201 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Stiolto Respimat | $19 | $201,004419 claims |
| PfizerEliquis | $101 | $188,405496 claims |
| Novo NordiskOzempic | $267 | $178,028137 claims |
| Lilly USA, LLCMounjaro, Trulicity | $161 | $163,643129 claims |
| Smith+NephewSantyl | $16 | $82,58036 claims |
| AbbVieLinzess, Restasis | $614 | $76,099127 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $413 | $64,96524 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $14 | $53,78597 claims |
| MerckJanuvia | $13 | $27,83868 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $25,16281 claims |
| NovartisEntresto | $44 | $23,80548 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Plaquemine
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.